Effect of Yin‐Xing‐Tong‐Zhi Tablets on Improving Vascular Cognitive Impairment No Dementia

Objective . Observe the effect of the Chinese herbal extracts, Yin‐Xing‐Tong‐Zhi, in tablet form, on improving vascular cognitive impairment no dementia (VCIND). Methods . Sixty‐eight patients with VCIND were divided randomly into treatment and placebo groups with oral administration of Yin‐Xing‐Tong‐Zhi tablets (YXTZTs) or placebo, respectively, for 24 weeks. Alzheimer’s Disease Assessment Scale‐Cognitive (ADAS‐Cog) subscale score, MMSE score, Clinician’s Interview‐Based Impression of Change Plus Caregiver Input (CIBIC‐Plus) score, expression of interleukin‐ (IL‐) 6, IL‐8, and tumor necrosis factor‐ (TNF‐) α in serum, and variation of blood‐lipid levels were evaluated at different time points. Results . At weeks 12 and 24, the scores for the ADAS‐Cog, CIBIC‐Plus, and MMSE of the treatment group were significantly lower than those of the control group ( P < 0.05). All clinical scales at week 24 of the control group were significantly different from those before treatment ( P < 0.05). Expression of IL‐6, IL‐8, and TNF‐ α in the two groups was reduced significantly with variation of the clinical scales of cognitive impairment. Conclusion . YXTZTs may delay the development of cognitive impairment in VCIND patients by modulating expression of VCIND‐associated proinflammatory factors.